Glycoprotein IIb-IIIa content and platelet aggregation in healthy volunteers and patients with acute coronary syndrome

References

• Coller BS, Shatill SJ. The GP IIb/IIIa (integrin αIIbβ3) odyssey: A technology-driven saga of a receptor with twists, turns and even a bend. Blood 2008; 112: 3011–3025
   PubMed Web of Science ®Google Scholar
• Plow EF, Pesho MM, Ma YQ. Integrin αIIbβ3. Platelets, 2nd, AD Michelson. Academic Press, Elsevier Inc., Amsterdam 2007; 165–178
   Google Scholar
• McEver RP, Baenziger NL, Majerus PW. Isolation and quantification of the platelet membrane glycoprotein deficient in thrombasthenia using a monoclonal hybridoma antibody. J Clin Invest 1980; 66: 1311–1318
   PubMedGoogle Scholar
• Coller BS. A new monoclonal antibody reports an activation-dependent change in the conformation and/or microenviroment of the platelet glycoprotein IIb/IIIa complex. J Clin Invest 1985; 76: 101–108
   PubMed Web of Science ®Google Scholar
• Wagner CL, Mascelli MA, Neblock DS, Weisman HF, Coller BS, Jordan RE. Analysis of GP IIb/IIIa receptor number by quantification of 7E3 binding to human platelets. Blood 1996; 8: 907–914
   Google Scholar
• Michelson AD. Flow cytometric analysis of platelet surface glycoproteins: Phenotypically distinct subpopulations of platelets in children with chronic myeloid leukemia. J Lab Clin Med 1987; 110: 346–354
   PubMed Web of Science ®Google Scholar
• Gawaz M, Neumann FJ, Ott I, May A, Rudiger S, Schomig A. Changes in membrane glycoproteins of circulating platelets after coronary stent implantation. Heart 1996; 76: 166–172
   PubMed Web of Science ®Google Scholar
• Quinn M, Deering A, Stewart M, Cox D, Foley B, Fitzgerald D. Quantifying GP IIb-IIIa receptor binding using 2 monoclonal antibodies. Discriminating abciximab and small molecular weight antagonists. Circulation 1999; 99: 2231–2238
   PubMed Web of Science ®Google Scholar
• Mazurov AV, Pevzner DV, Khaspekova SG, Dudnik OA, Byzova TV, Vlasik TN, et al. Inhibition of thrombocyte aggregation by F(ab')2-fragments of monoclonal antibodies FraMon (CRC64) to glycoproteins IIb-IIIa. Ter Arkh 2001;73:66–73. (In Russian).
   Google Scholar
• O’Halloran AM, Curtin R, O’Connar F, Dooley M, Fitzgerald A, O’Brian JK, et al. The impact of genetic variation in the region of the GP IIIa gene on PlA2 expression bias and GP IIb-IIIa receptor density in platelets. Br J Haematol 2006; 132: 494–502
   PubMedGoogle Scholar
• Sirotkina OV, Zabotina AM, Taraskina AE, Sivachenko EB, Zueva EE, Kadinskaya MI, et al. Participation of IIb-IIIa glycoprotein in spontaneous platelet aggregation. Bull Exp Biol Med 2007; 143: 422–425
   PubMedGoogle Scholar
• Sirotkina OV, Khaspekova SG, Zabotina AM, Shimanova YV, Mazurov AV. Effects of platelet glycoprotein IIb-IIIa number and glycoprotein IIIa Leu33Pro polymorphism on platelet aggregation and sensitivity to glycoprotein IIb-IIIa antagonists. Platelets 2007; 18: 506–514
   PubMed Web of Science ®Google Scholar
• Khaspekova SG, Sirotkina OV, Shimanova IuV, Mazurov AV. Variations in glycoprotein IIb-IIIa (alphaIIb/beta3-integrin) content in healthy donors. Influence on platelet aggregation activity and efficacy of aspirin action. Biomed Khim 2008; 54:361–371. (In Russian).
   Google Scholar
• Thcheng JE, Ellis SG, George BS, Kereiakes DJ, Kleiman NS, Talley JD, et al. Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty. Circulation 1994; 90: 1757–1764
   PubMedGoogle Scholar
• Mazurov AV, Pevzner DV, Antonova OA, Byzova TV, Khaspekova SG, Semenov AV, et al. Safety, inhibition of platelet aggregation and pharmacokinetics of F(ab’)2 fragments of the anti-glycoprotein IIb-IIIa monoclonal antibody FRaMon in high-risk coronary angioplasty. Platelets 2002; 13: 465–477
   PubMedGoogle Scholar
• Gabbasov ZA, Popov EG, Gavrilov IYu, Pozin EYa. Platelet aggregation: The use of optical density fluctuations to study microaggregate formation in platelet suspension. Thromb Res 1989; 54: 215–223
   PubMed Web of Science ®Google Scholar
• Gabbasov Z, Parfyonova Y, Popov E, Gavrilov I, Anuchin V, Dubov P, Djakonova Y. Association of platelet function in hypertensive patients with left ventricular hyperthrophy, transient myocardial ischemia, and coronary artery disease. Platelets 1998; 9: 191–195
   PubMed Web of Science ®Google Scholar
• Eto K, Takeshita S, Ochiai M, Ozaki Y, Sato T, Isshiki T. Platelet aggregation in acute coronary syndromes: Use of a new aggregometer with laser light scattering to assess platelet aggregability. Cardiovasc Res 1998; 40: 223–229
   PubMed Web of Science ®Google Scholar
• Afshar-Kharghan V, Vijayan KV, Bray PF. Platelet polymorphism. Platelets, 2nd, AD Michelson. Academic Press, Elsevier Inc., Amsterdam 2007; 281–307
   Google Scholar
• Weiss EJ, Bray PF, Tayback M, Schulman SP, Kickler TS, Becker LC, et al. A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis. N Engl J Med 1996; 334: 1090–1094
   PubMed Web of Science ®Google Scholar
• Reiner AP, Siscovick DS, Rosendaal FR. Platelet glycoprotein gene polymorphisms and risk of thrombosis: Facts and fancies. Rev Clin Exp Hematol 2001; 5: 262–287
   PubMedGoogle Scholar
• Burr D, Doss H, Cooke GE, Goldschmidt-Clermont PJ. A meta-analysis of studies on the association of the platelet PlA polymorphisms of glycoprotein IIIa and risk of coronary heart disease. Stat Med 2003; 22: 1741–1760
   PubMed Web of Science ®Google Scholar
• Di Castelnuovo A, de Gaetano G, Benedetta Donati M, Iacoviello L. Platelet glycoprotein IIb/IIIa polymorphism and coronary artery disease: Implication for clinical practice. Am J Pharmacogenomics 2005; 5: 93–99
   PubMedGoogle Scholar
• Vijayan KV, Bray PF. Molecular mechanisms of prothrombotic risk due to genetic variations in platelet genes: Enchanced outside-in signaling through the Pro33 variant of integrin β3. Exp Biol Med 2006; 231: 505–513
   PubMed Web of Science ®Google Scholar
• Vijayan KV, Goldschmidt-Clermont PJ, Roos C, Bray PF. The Pl(A2) polymorphism of integrin beta(3) enchances outside-in signaling and adhesive functions. J Clin Invest 2000; 105: 793–802
   PubMedGoogle Scholar
• Goodall AH, Curzen N, Panesar M, Hurd C, Knight CJ, Ouwehand WH, Fox KM. Increased binding of fibrinogen to glycoprotein IIIa-Proline33 (HPA-1b, PlA2, Zwb) positive platelets in patients with cardiovascular disease. Eur Heart J 1999; 20: 742–747
   PubMed Web of Science ®Google Scholar
• Michelson AD, Furman MI, Goldschmidt-Clermont P, Mascelli MA, Hendrix C, Coleman L, et al. Platelet GP IIIa PlA polymorphisms display different sensitivities to agonists. Circulation 2000; 101: 1013–1018
   PubMed Web of Science ®Google Scholar
• Huang T, Sahud MA. Association of C807T, Pl(A), and -5 C/T Kozak genotypes with density of glycoprotein receptors on platelet surface. Thromb Res 2003; 112: 147–150
   PubMedGoogle Scholar
• Feng D, Lindpaintner K, Larson MG, Rao VS, O’Donnell CJ, Lipinska I, et al. Increased platelet aggregability associated with platelet GPIIIa PlA2 polymorphism: The Framingham Offspring Study. Artherioscler Thromb Vasc Biol 1999; 19: 1142–1147
   PubMed Web of Science ®Google Scholar
• Bennett JS, Catella-Lawson F, Rut AR, Vilaire G, Qi W, Kapoor SC, Murphy S, FitzGerald GA. Effect of the PlA2 alloantigen on the function of 3-integrins in platelets. Blood 2001; 97: 3093–3099
   PubMedGoogle Scholar
• Feng D, Lindpaintner K, Larson MG, O’Donnell CJ, Lipinska I, Stherland PA, et al. Platelet glycoprotein IIIa Pla polymorphism, fibrinogen, and platelet aggregability. The Framingham heart study. Circulation 2001; 104: 140–144
   PubMed Web of Science ®Google Scholar
• Meade TW, Vickers MV, Thompson SG, Stirling Y, Haines AP, Miller GJ. Epidimiological characteristics of platelet aggregability. Br Med J 1985; 90: 428–432
   Google Scholar
• Zurn CS, Geisler T, Gawaz M. ADP-receptor blockage: A case for personalized pharmacotherapy. Thromb Haemost 2010; 103: 496–506
   PubMedGoogle Scholar
• Mazurov AV, Vinogradov DV, Vlasik TN, Repin VS, Booth WJ, Berndt MC. Characterization of an antiglycoprotein Ib monoclonal antibody that specifically inhibits platelet-thrombin interaction. Thromb Res 1991; 62: 673–684
   PubMed Web of Science ®Google Scholar
• Leytin V, Shapiro H, Radney J. Flow cytometric analysis of the platelet surface area and surface density of glycoprotein IIb-IIIa of unactivated human platelets of various sizes. Biochem Biophys Res Commun 1996; 226: 94–100
   PubMedGoogle Scholar
• Tschoepe D, Kaufmann L, Schauseil S, Kehrel B, Ostermann H, Gries FA. Evidence for abnormal platelet glycoprotein expression in diabetes mellitus. Eur J Clin Invest 1990; 20: 166–170
   PubMed Web of Science ®Google Scholar
• Giles H, Smith RE, Martin JF. Platelet glycoprotein IIb-IIIa and size are increased in acute myocardial infarction. Eur J Clin Invest 1994; 24: 69–72
   PubMed Web of Science ®Google Scholar
• Frojmovic M, Wong T. Dynamic measurements of the platelet membrane glycoproteinIIb-IIIa receptor for fibrinogen by flow cytometry. II. Platelet size-dependent subpopulations. Biophys J 1991; 59: 828–837
   PubMed Web of Science ®Google Scholar
• Guthikonda S, Alviar CL, Vaduganathan M, Arikan M, Tellez A, DeLao T, et al. Role of reticulated platelets and platelet size heterogeneity on platelet activity after dual antiplatelet therapy with aspirin and clopidogrel in patients with stable artery disease. J. Am Coll Cardiol 2008; 52: 743–743
   PubMed Web of Science ®Google Scholar
• Thompson CB, Jakubowsky JA, Quinn PG, Deykin D, Valeri CR. Platelet size as a determinant of platelet function. J Lab Clin Med 1983; 101: 205–213
   PubMed Web of Science ®Google Scholar
• Wong T, Pedvis L, Frojmovic M. Platelet size affects both micro- and macro-aggregation: Contribution of platelet number, volume fraction and cell surface. Thromb Haemost 1989; 62: 733–741
   PubMedGoogle Scholar
• Chu SG, Becker RC, Berger PB, Bhatt DL, Eikelboom JW, Konkie B, et al. Mean platelet volume as a predictor of cardiovascular risk: A systematic review and meta-analysis. J Thromb Haemost 2010; 8: 148–156
   PubMed Web of Science ®Google Scholar